The Dish’s Weekly Biotechnology News Wrap Up – February 22, 2019
This week’s headlines include: CRISPR corrects DMD in mice for a year in Sarepta-supported study, DNA Gets a New — and Bigger — Genetic Alphabet, World Health Organization Forms Committee To Guide Editing Of Human Genes, and CRISPR Sleight of Hand Generates Immunologically Invisible Stem Cells.
Podcasts:
Check out our podcast channel. We have over 25 great podcasts covering drug discovery, stem cell culture, upstream and downstream biomanufacturing and more! Click below to download from iTunes or Google play:
In Case You Missed It, Recent Articles on Cell Culture Dish and Downstream Column:
Enzymes for Cellular Lysis or Protoplast Formation: Bacteria, Yeasts, and Plant
Digesting cell walls using enzymes is a critical component of many scientific approaches such as cellular lysis, proto/spheroplast formation, and numerous other approaches. The use of enzymes has advantages over physical or chemical methods because of its specificity, the use of milder conditions and lower shear stress. Since cell walls differ in composition between types of cells, it is important to use an enzyme with the correct specificity and activity for the application. Other consideration in choosing an enzyme include the purity and need for other reagents or additional procedures related to the use of that particular enzyme…
Integrating bioprocessing steps to improve efficiency and reduce cost
In this podcast, we interviewed Dr. Rick Morris, Senior Vice President, R&D, Biotech, Pall Life Sciences, about integrating bioprocessing steps to improve efficiency, reduce cost and address current challenges in the industry. Specifically we looked at how upstream and downstream can be more integrated and how to increase integration in existing facilities…
Cool Tool – Advanced Bioprocess Controller Puts Cell Culture on Autopilot
Bioprocess controllers are an important part of a bioprocess lab. In many bioprocess labs several experiments are running simultaneously sometimes using multiple cell types with different modes and at varying scale. A bioprocess controller can help to simplify these demands, provided that the controller isn’t overly complex or challenging to operate. The goal is finding a bioprocess controller that permits maximum flexibility while still being straightforward and simple to use…
Cool Tool: PEIpro® enables seamless scale-up of transient transfection for therapeutic viral vector manufacturing
During process development (PD) for virus vector production, choosing raw materials from reliable suppliers that can provide the highest quality to meet Advanced Therapy Medicinal Products (ATMP) GMP guidelines is key and will facilitate transition to large-scale clinical-grade virus manufacturing. With the launch of commercially available PEIpro®-GMP, Polyplus-transfection® SA now provides a complete PEIpro® product range to address concerns often raised with transient transfection for large scale manufacturing of viral vectors: efficiency, reproducibility and scalability…
Expediting Cell and Gene Therapy Workflows
In this podcast and accompanying article, we interviewed Mr. Dave Eansor President of the Protein Sciences Segment at Bio-Techne and Dr. Sean Kevlahan, Senior Director of Cell and Gene Therapy at Bio-Techne about new technologies that can be implemented to expedite cell therapy and gene therapy workflows and facilitate the path from bench to clinic…
Scalable Protein A Chromatography for High-Throughput Process Development
Process development is a critical part of biomanufacturing, but it can be very time and resource intensive. With recent industry initiatives around speed to market, process development is an area that could really benefit from high throughput solutions. One high-throughput process development tool for chromatography is the use of 96-well plates. These plate platforms permit automated screening of large numbers of conditions very efficiently and use only a small amount of material for testing. This platform is great for screening but requires bridging experiments to translate results to process scale. In addition, automating the 96-well process requires investment in liquid handling equipment in order to reach the full potential of the platform…
Utilizing High-Throughput Process Development Tools to Create a Purification Process for a Biosimilar Molecule
Biosimilar molecules have some unique manufacturing requirements that must be taken into account when planning process development. The requirements for process development typically require a good deal of selectivity, cost-efficiency and the need to meet aggressive timelines. These lend themselves to a process development approach that incorporates high throughput…
Designing a Viral Clearance Study – A Step by Step Tutorial
Viral clearance testing is a regulatory requirement and critical part of the overall approval process for all biologics. Viral clearance testing is performed at two points in biologics development. Before Phase I clinical trials, viral clearance studies are conducted to demonstrate the capability of a downstream purification process to eliminate potential viral contaminants…
High Throughput Process Development in Biomanufacturing – Current Challenges and Benefits
Process development is and has always been a key component in successful scale-up of bioprocesses to commercial manufacture scale. At the Fourth High Throughput Process Development Conference in Toledo, Spain, several methods for high throughput process development were discussed for both upstream and downstream applications. Challenges and benefits were described along with ideas on where the industry can go from here. The proceedings were collected in a recently published report, “HTPD – High Throughput Process Development,” and include extended abstracts of talks presented at the conference. The report is very informative and I have summarized some key areas of focus in this article. We were also fortunate to be able to interview one of the conference chairs, Mats Gruvegard, GE Healthcare Life Sciences about what he saw as key takeaways from the conference and where he sees the future of high throughput process development heading…
Monolithic Chromatography Enables Process Intensification of Virus Purification
Monoliths are unique from other forms of chromatography media for several reasons. Monolith architecture consists of highly interconnected convective channels that are distributed throughout the entire bed. The large channels are easily available for purification even for large biomolecules. This unique architecture also creates a void-less space, thus significantly reducing shear and product loss. In monoliths, the mass transport is also exclusively convective and laminar which means that all solutes flow with the current regardless of size and require only a few seconds of residence time…
Conferences:
Americas Antibody Congress 2019
In the 14 years that the European Antibody Congress has run in Basel, Switzerland, there have been countless breakthroughs, advancements and achievements that not only were showcased for the first time at the European Antibody Congress but were also born out of collaborations and partnerships that were catalysed by, or initiated, at the European Antibody Congress. This is why we are launching the Americas Antibody Congress in San Diego this March to bring the amazing antibody work we’ve been showcasing…
BioProcess International West
March 11-14, 2019
Santa Clara Convention Center, Santa Clara, California, USA
Overcome Your Upstream and Downstream Challenges at BPI US West 2019
Meet the global CMOs, CROs, suppliers and technology leaders who can accelerate your biological products to market by getting your 2-day exhibit hall pass to BioProcess International US West, held March 11-12, 2019 at the Santa Clara Convention Center in California. Passes start at $399, but readers of Cell Culture Dish can save 50% on an exhibit hall pass when you register with VIP Code DISH50 by March 1, 2019 (new registrations only). For full details and to register, visit https://lifesciences.knect365.
Headlines:
“CRISPR corrects DMD in mice for a year in Sarepta-supported study,” FierceBiotech
“In 2017, Duchenne muscular dystrophy drug maker Sarepta signed a deal with Duke University to research potential cures for the disease using the gene-editing system CRISPR. Now the Duke lab at the center of that research pact is reporting promising results from a trial of CRISPR in mouse models of DMD…”
“DNA Gets a New — and Bigger — Genetic Alphabet,” The New York Times
“DNA is spelled out with four letters, or bases. Researchers have now built a system with eight. It may hold clues to the potential for life elsewhere in the universe and could also expand our capacity to store digital data on Earth..”
“World Health Organization Forms Committee To Guide Editing Of Human Genes,” NPR
“The World Health Organization Thursday announced the formation of an international committee aimed at establishing uniform guidelines for editing human DNA in ways that can be passed down to future generations. The 18-member committee “will examine the scientific, ethical, social and legal challenges associated with human genome editing,” according to the WHO announcement…”
“CRISPR Sleight of Hand Generates Immunologically Invisible Stem Cells,” Genetic Engineering News
“An international research team has used CRISPR-Cas9 gene editing to render induced pluripotent stem cells (iPSCs) invisible to the immune system, a bioengineering sleight of hand that initial in vivo tests suggest could open the door to generating stem cells for universal transplantation. The new approach, developed by scientists at the University of California, San Francisco (UCSF), involves disabling two histocompatibility complex genes, and overexpressing the transmembrane protein CD47 on iPSCs. In vivo tests suggested that engineered human iPSC-derived cardiac cells were undetected by the immune system in mouse recipients, and showed evidence of rudimentary tissue differentiation…”